Regeneron Pharmaceuticals
Stock Forecast, Prediction & Price Target

Regeneron Pharmaceuticals (REGN) stock Price Target by analysts

Last Year
Average Price Target

$1,145.92

Potential upside: 99.36%

Based on 10 analysts

Regeneron Pharmaceuticals price prediction

Strike.market

What is Regeneron Pharmaceuticals stock analysts` prediction?

Regeneron Pharmaceuticals stock forecast: Based on 10 Wall Street analysts` predicted price targets for Regeneron Pharmaceuticals in the last 3 months, the avarage price target is $1,145.92, with a high forecast of $NaN. The average price target represents a 99.36% change from the last price of $574.79.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Regeneron Pharmaceuticals stock Price Target by analysts

Full breakdown of analysts given Regeneron Pharmaceuticals price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Evan David Seigerman
BMO Capital
25%
1/4
10 months ago $1,190 107.03% upside $843.6 StreetInsider
Previous targets (3)
Christopher Raymond
Piper Sandler
0%
0/1
10 months ago $1,195 107.90% upside $843.6 StreetInsider
Previous targets (0)
Andrew Berens
Leerink Partners
0%
0/2
10 months ago $880 53.09% upside $843.6 StreetInsider
Previous targets (1)
Cory Kasimov
Evercore ISI
0%
0/3
10 months ago $1,170 103.55% upside $838.2 StreetInsider
Previous targets (2)
Cory Kasimov
Evercore ISI
0%
0/3
11 months ago $1,175 104.42% upside $941.39 StreetInsider
Previous targets (2)
Mohit Bansal
Wells Fargo
50%
1/2
11 months ago $1,050 82.67% upside $962.34 StreetInsider
Previous targets (1)
Salveen Richter
Goldman Sachs
50%
1/2
12 months ago $1,292 124.77% upside $1,091.98 StreetInsider
Previous targets (1)
David Risinger
Leerink Partners
0%
0/1
12 months ago $1,077 87.37% upside $1,091.98 TheFly
Previous targets (0)
Thomas Klee
Truist Financial
0%
0/1
12 months ago $1,200 108.77% upside $1,091.98 TheFly
Previous targets (0)
Brian Skorney
Robert W. Baird
0%
0/1
12 months ago $940 63.53% upside $1,091.98 StreetInsider
Previous targets (0)
Evan David Seigerman
BMO Capital
25%
1/4
12 months ago $1,300 126.16% upside $1,159.95 StreetInsider
Previous targets (3)
Brian Abrahams
RBC Capital
0%
0/7
12 months ago $1,282 123.03% upside $1,139.41 TheFly
Previous targets (6)
Christopher Raymond
Raymond James
0%
0/3
about 1 year ago $1,242 116.07% upside $1,187.66 TheFly
Previous targets (2)
Geoff Meacham
Bank of America Securities
0%
0/1
about 1 year ago $805 40.05% upside $1,077.48 TheFly
Previous targets (0)
Brian Abrahams
RBC Capital
0%
0/7
about 1 year ago $1,240 115.73% upside $1,093.14 TheFly
Previous targets (6)
Christopher Raymond
Raymond James
0%
0/3
about 1 year ago $1,166 102.85% upside $1,063.6 StreetInsider
Previous targets (2)
Yatin Suneja
Guggenheim
0%
0/1
about 1 year ago $1,180 105.29% upside $1,085.62 TheFly
Previous targets (0)
Trung Huynh
UBS
0%
0/1
about 1 year ago $1,250 117.47% upside $1,092.31 TheFly
Previous targets (0)
Terence Flynn
Morgan Stanley
0%
0/1
about 1 year ago $1,182 105.64% upside $1,071.12 TheFly
Previous targets (0)
Jasper Hellweg
Argus Research
50%
1/2
about 1 year ago $1,170 103.55% upside $1,063.89 TheFly
Previous targets (1)
Brian Abrahams
RBC Capital
0%
0/7
about 1 year ago $1,299 125.99% upside $1,022.03 Benzinga
Previous targets (6)
Brian Abrahams
RBC Capital
0%
0/7
about 1 year ago $1,229 113.81% upside $1,010.54 TheFly
Previous targets (6)
Brian Abrahams
RBC Capital
0%
0/7
over 1 year ago $1,200 108.77% upside $998.64 StreetInsider
Previous targets (6)
Evan David Seigerman
BMO Capital
25%
1/4
over 1 year ago $1,082 88.24% upside $992.47 StreetInsider
Previous targets (3)
Christopher Raymond
Raymond James
0%
0/3
over 1 year ago $1,000 73.97% upside $982.29 StreetInsider
Previous targets (2)
Cory Kasimov
Evercore ISI
0%
0/3
over 1 year ago $1,150 100.07% upside $976.96 StreetInsider
Previous targets (2)
Brian Abrahams
RBC Capital
0%
0/7
over 1 year ago $1,185 106.16% upside $937.61 StreetInsider
Previous targets (6)
Akash Tewari
Jefferies
66.67%
2/3
over 1 year ago $1,060 84.41% upside $911.78 StreetInsider
Previous targets (2)
Brian Abrahams
RBC Capital
0%
0/7
over 1 year ago $1,189 106.85% upside $921.34 StreetInsider
Previous targets (6)
Matthew Harrison
Morgan Stanley
75%
3/4
over 1 year ago $1,115 93.98% upside $965.47 StreetInsider
Previous targets (3)
Brian Abrahams
BMO Capital
0%
0/1
over 1 year ago $1,076 87.19% upside $934.06 Benzinga
Previous targets (0)
Andrew Berens
Leerink Partners
0%
0/2
over 2 years ago $976 69.80% upside $820 StreetInsider
Previous targets (1)
Akash Tewari
Jefferies
66.67%
2/3
over 2 years ago $925 60.92% upside $819.68 StreetInsider
Previous targets (2)
Unknown
EF Hutton
N/A
over 2 years ago $853 48.40% upside $769.94 Benzinga
N/A
Unknown
Leerink Partners
N/A
over 2 years ago $834 45.09% upside $783.13 Benzinga
N/A
Unknown
Guggenheim
N/A
almost 3 years ago $915 59.18% upside $707.63 Benzinga
N/A
Unknown
Goldman Sachs
N/A
almost 3 years ago $970 68.75% upside $726.93 Benzinga
N/A
Unknown
Canaccord Genuity
N/A
almost 3 years ago $750 30.48% upside $710.21 Benzinga
N/A
Unknown
Piper Sandler
N/A
almost 3 years ago $775 34.83% upside $701.15 Benzinga
N/A
Unknown
Wells Fargo
N/A
almost 3 years ago $800 39.18% upside $718.83 Benzinga
N/A
Parker Lane
Stifel Nicolaus
100%
1/1
almost 3 years ago $13 -97.73% downside $708.85 Benzinga
Previous targets (0)
Unknown
Barclays
N/A
almost 3 years ago $815 41.79% upside $708.85 Benzinga
N/A
Matthew Harrison
Morgan Stanley
75%
3/4
almost 3 years ago $851 48.05% upside $708.85 TheFly
Previous targets (3)
Akash Tewari
Jefferies
66.67%
2/3
almost 3 years ago $675 17.43% upside $708.85 TheFly
Previous targets (2)
Matthew Harrison
Morgan Stanley
75%
3/4
about 3 years ago $625 8.73% upside $628.71 Pulse 2.0
Previous targets (3)
Unknown
BMO Capital
N/A
about 3 years ago $788 37.09% upside $614.96 Benzinga
N/A
Unknown
Morgan Stanley
N/A
about 3 years ago $625 8.73% upside $618.54 Benzinga
N/A
Unknown
Morgan Stanley
N/A
about 3 years ago $619 7.69% upside $604.3 Benzinga
N/A
Kennen MacKay
RBC Capital
100%
2/2
about 3 years ago $638 10.99% upside $597.62 Pulse 2.0
Previous targets (1)
Mohit Bansal
Wells Fargo
50%
1/2
about 3 years ago $735 27.87% upside $571.81 Pulse 2.0
Previous targets (1)

Regeneron Pharmaceuticals Financial Estimates

Regeneron Pharmaceuticals Revenue Estimates

Regeneron Pharmaceuticals EBITDA Estimates

Regeneron Pharmaceuticals Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$16.07B
 
N/A
$12.17B
 
-24.25%
$13.11B
 
7.75%
Avg: $14.93B
Low: $13.91B
High: $15.57B
avg. 13.87%
Avg: $16.03B
Low: $15.14B
High: $17.03B
avg. 7.37%
Avg: $17.24B
Low: $16.27B
High: $18.31B
avg. 7.52%
Avg: $18.33B
Low: $17.31B
High: $19.47B
avg. 6.33%
Net Income
 
% change YoY
$8.07B
 
N/A
$4.33B
 
-46.27%
$3.95B
 
-8.86%
Avg: $4.45B
Low: $3.58B
High: $5.12B
avg. 12.79%
Avg: $5.21B
Low: $4.37B
High: $6.96B
avg. 17.02%
Avg: $6.68B
Low: $6.19B
High: $7.22B
avg. 28.07%
Avg: $7.28B
Low: $6.75B
High: $7.87B
avg. 8.96%
EBITDA
 
% change YoY
$9.38B
 
N/A
$5.17B
 
-44.86%
$4.69B
 
-9.27%
Avg: $6.38B
Low: $5.94B
High: $6.65B
avg. 35.96%
Avg: $6.85B
Low: $6.46B
High: $7.27B
avg. 7.37%
Avg: $7.36B
Low: $6.95B
High: $7.82B
avg. 7.52%
Avg: $7.83B
Low: $7.39B
High: $8.32B
avg. 6.33%
EPS
 
% change YoY
$76.4
 
N/A
$40.51
 
-46.97%
$37.05
 
-8.54%
Avg: $37.85
Low: $31.57
High: $45.07
avg. 2.14%
Avg: $45.39
Low: $38.51
High: $61.22
avg. 19.94%
Avg: $58.78
Low: $54.5
High: $63.53
avg. 29.49%
Avg: $64.05
Low: $59.38
High: $69.23
avg. 8.96%
Operating Expenses
 
% change YoY
$4.68B
 
N/A
$5.61B
 
19.86%
$7.25B
 
29.11%
Avg: $2.62B
Low: $2.44B
High: $2.74B
avg. -63.77%
Avg: $2.82B
Low: $2.66B
High: $2.99B
avg. 7.37%
Avg: $3.03B
Low: $2.86B
High: $3.22B
avg. 7.52%
Avg: $3.22B
Low: $3.04B
High: $3.42B
avg. 6.33%

FAQ

What is Regeneron Pharmaceuticals stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 16.71% in 2025-2028.

We have gathered data from 16 analysts. Their low estimate is 3.58B, average is 4.45B and high is 5.12B.

What is Regeneron Pharmaceuticals stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 8.77% in 2025-2028.

We have gathered data from 20 analysts. Their low revenue estimate is $13.91B, average is $14.93B and high is $15.57B.

What is Regeneron Pharmaceuticals stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 15.13% in 2025-2028.

We have gathered data from 16 analysts. Their low earnings per share estimate is $31.57, average is $37.85 and high is $45.06.

What is the best performing analyst?

In the last twelve months 10 analysts have been covering Regeneron Pharmaceuticals stock. The most successful analyst is Evan David Seigerman whose win rate is 25%. He has correctly predicted 1/4 price targets.